Repros Therapeutics (RPRX) PT Lifted to $30 at BofA/Merrill Lynch; Sees Higher Chance for Androxal Approval

In a note dated August 28th, BofA/Merrill Lynch analyst Steve Byrne boosted his price target on Buy-rated Repros Therapeutics (NASDAQ: RPRX) to $30.00 (from $27.00) which followed positive topline data from the ‘305 study of Androxal vs. AndroGel.

Byrne noted results were better than expected, with no obvious safety issues. They raised their probability of approval to 85% (from 80%).

The analyst also noted the second phase 3 trial, ‘304, is expected to read out by October (~four weeks behind ‘305) followed by an analyst day on October 31.

For an analyst ratings summary and ratings history on Repros Therapeutics click here. For more ratings news on Repros Therapeutics click here.

Shares of Repros Therapeutics closed at $21.58 yesterday.

You May Also Be Interested In

• Boston Scientific (BSX) PT Raised to $83 at Stifel
• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• Goldman Sachs Downgrades Zhejiang Huayou Cobalt Co Ltd. (603799:CH) to Sell